14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
RAPP vs NUVB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPP carries a Unified Composite Score of 50.9/100 (HOLD) at $23.16 (N/M Forward P/E, -838.1% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).
Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPP vs NUVB. Trailing 12-month operating profitability (RAPP -838.1% vs NUVB -61.2%) and valuation multiples (RAPP N/M vs NUVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RAPP vs NUVB Key Questions & Quantitative Answers
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPP carries a Unified Composite Score of 50.9/100 (HOLD) at $23.16 (N/M Forward P/E, -838.1% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: RAPP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). On trailing 12-month operating scale, RAPP generates $20M in USD-normalized revenue versus $202M for NUVB. In operating R&D and SG&A reinvestment, RAPP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.
NUVB screens cheaper on headline valuation multiples. RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 66.7x EV/Revenue (unreported FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPP (-33.3% ROE) versus NUVB (-49.1% ROE) capital efficiency.
In options market volatility and institutional positioning, RAPP carries 106.2% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 92% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.